Strong Organic Revenue Growth
Elanco achieved 9% organic constant currency revenue growth in Q3 2025, outperforming the high end of guidance for revenue, adjusted EBITDA, and adjusted EPS.
U.S. Farm and Pet Health Growth
U.S. Farm Animal segment grew by 20% and U.S. pet health grew by 9%, marking the 9th consecutive quarter of underlying total growth.
Innovation Revenue Increase
Innovation products achieved $655 million in year-to-date revenue, exceeding expectations and leading to a full-year guidance increase by $100 million.
Credelio Quattro Success
Credelio Quattro reached blockbuster status with $100 million in sales in less than 8 months, driven by strong demand and differentiation.
Improved Leverage Ratio
Elanco improved its net leverage ratio to 3.7x by the end of Q3 2025, faster than planned, with expectations to end the year between 3.7x and 3.8x.
Refinancing of Term Loan B
Successfully refinanced $2.1 billion Term Loan B facility, extending maturities through 2032, improving the capital structure.